#Keytruda

Total 2 articles

Microscopic view of mRNA vaccine attacking cancer cells

Moderna Merck mRNA Cancer Vaccine Results: 50 Percent Risk Reduction

Moderna and Merck's mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence risk by 50% in a 5-year study. Read the latest Phase 2 trial insights.

Jan 22, 2026

Interior of a Merck lab with a $70 billion revenue growth chart

EconomyEN

Merck Targets $70 Billion Revenue by mid-2030s to Counter Keytruda Patent Cliff

Merck (MSD) announced a revenue target of $70 billion by the mid-2030s, driven by new growth opportunities and a diversified pipeline to offset Keytruda's patent expiration.

Jan 13, 2026